THC + CBD and Memory Study

• Status: Not yet recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hartford Hospital
• Collaborator: Yale University
• Treatments: Dronabinol

Criteria

Inclusion Criteria:

• Right-handed

• Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months)

• Medically healthy (as determined by medical history and treatment)

• Adequate comprehension of English in order to complete study materials

• Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe)

Exclusion Criteria:

• Participant currently uses psychoactive medications or substances

• Psychiatric diagnoses (determined by DSM-V)

• Participant heavily or regularly uses MJ (more than 1x/month in the past year)

• Current or past substance dependence (including MJ)

• Positive urine toxicology screens

• Positive pregnancy screens

• MRI contraindications (e.g., heart pacemaker)